Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
75 hedge funds and large institutions have $176M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$10.3M |
| 4 |
JCM
JS Capital Management
New York
|
+$10.3M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.3M |
Top Sellers
PRDS Hedge Fund Activity: Q1 2021 in Review
75 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q1 2021, worth a combined $176M.
Buyers outnumbered sellers: 75 funds opened new PRDS positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $17.7M.
- 75 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $176M of Pardes Biosciences, Inc. Common Stock stock for Q1 2021.
- 75 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +75 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q1 2021 was T. Rowe Price Associates, an estimated $17.7M added.
Based on aggregated 13F filings for Q1 2021.